REGENERON PHARMACEUTICALS, INC.
REGNNasdaqGSBiotechnology • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for REGN
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for REGN
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 30 Jul 2026
Quarterly Earnings Exceed Consensus
Reported non-GAAP EPS of $14.29 per share for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $10.21 per share.
Dupixent Sales Reach Record
Dupixent global net sales, recorded by Sanofi, increased 38% to a new all-time high of $6.0 billion.
Manufacturing Interruption Resolved
Bulk manufacturing production at the Limerick, Ireland facility returned to normal levels by the end of the second quarter of 2026, following a temporary interruption that did not impact product availability.
Share Repurchases Continue
The company repurchased $2.0 billion of common stock during the six months ended June 30, 2026, with $2.5 billion remaining available under its repurchase programs.
Price Chart
NASDAQ:REGN via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
REGNREGENERON PHARMACEUTICALS, INC. | $794.19 | $81.8B | 18.6x | 14.8x | +9.3% | — | 4.6% |
Company Profile
About the Company
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Next Earnings Date
Oct 28, 2026
Loading latest news...